文献速递银屑病与炎症性皮肤病

阿达木单抗在银屑病登记研究中的真实世界安全性系统综述

Systematic review of the real-world evidence of adalimumab safety in psoriasis registries.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-08-28

本系统综述检索多个数据库,纳入10项银屑病登记研究中成人患者使用阿达木单抗的安全性数据。ESPRIT登记(N=6059)报告不良事件总发生率为22.2/100患者年,严重不良事件为4.3/100患者年;感染、心血管事件及恶性肿瘤发生率在不同登记研究间总体一致,支持阿达木单抗已知的长期安全性特征。

要点

  • ESPRIT登记(N=6059)中阿达木单抗不良事件总发生率为22.2/100患者年。
  • ESPRIT登记中严重不良事件发生率为4.3/100患者年。
  • 不同银屑病登记研究的真实世界安全性数据与临床试验已知特征一致。

核心结论

  • 真实世界安全性数据在不同银屑病登记研究间一致,支持阿达木单抗现有的长期安全性特征。

研究设计与样本

  • 系统综述,检索BIOSIS Previews、Current Contents Search、Derwent Drug File、EMBASE、EMBASE Alert、EMCare、MEDLINE、SciSearch数据库。
  • 筛选425篇文献摘要,排除401篇(会议摘要208篇;论文193篇),全文筛选再排除14篇(无阿达木单抗数据10篇;无安全性数据2篇;无治疗中数据1篇;非英文1篇),最终纳入10篇来自银屑病登记研究的英文稿件。

主要发现

  • ESPRIT登记(N=6059)报告不良事件总发生率为22.2/100患者年(事件数4273),严重不良事件发生率为4.3/100患者年(事件数827)。
  • 四项研究报告感染发生率为7.7-14.7/100患者年,严重感染发生率为<0.6-2.0/100患者年。
  • 三项研究报告心血管相关事件:ESPRIT中每一主要心脏事件≤0.1/100患者年,PsoBest中主要心脏事件<0.5/100患者年,DERMBIO中2例患者(<1%)发生严重心血管事件。
  • 三项研究报告恶性肿瘤:任何恶性肿瘤0.9/100患者年,排除非黑色素瘤皮肤癌(NMSC)的恶性肿瘤<0.6/100患者年,NMSC为0.6-<0.5/100患者年。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Long-term safety of adalimumab in psoriasis clinical studies has been established. The objective of this research was to review real-world evidence of adalimumab safety from registries of adult patients with psoriasis treated in clinical practice. Databases (BIOSIS Previews, Current Contents Search, Derwent Drug File, EMBASE, EMBASE Alert, EMCare, MEDLINE, SciSearch) were searched for psoriasis registries with adalimumab safety data. Eligible papers were English language manuscripts (conference abstracts excluded) from psoriasis registries presenting safety data for adult patients with psoriasis receiving adalimumab. The incidence and rate (events/100 patient-years [PY]) of adverse events (AEs), serious AEs (SAEs) and AEs of special interest are reported. Abstracts of 425 publications were screened, and 401 publications excluded (208 conference abstracts; 193 papers). Remaining manuscripts were fully screened; 14 were excluded (no adalimumab data, n = 10; no safety data, n = 2; no on-treatment data, n = 1; not English, n = 1), and 10 selected. Overall rates of AEs (4273 [22.2/100PY]) and SAEs (827 [4.3/100PY]) were reported in the ESPRIT registry (N = 6059). Rates of infections (7.7-14.7/100PY) and serious infections (<0.6-2.0/100PY) were reported in four studies. Cardiovascular-related events were reported in three studies: ≤0.1/100PY per major cardiac event in ESPRIT, <0.5/100PY major cardiac events in PsoBest and serious cardiovascular events in two patients (<1%) in DERMBIO. Malignancies were reported in three studies (any malignancy, 0.9/100PY; malignancies excluding non-melanoma skin cancer [NMSC], <0.6/100PY; NMSC, 0.6-<0.5/100PY). These findings suggest that real-world safety of adalimumab is consistent across different psoriasis registries, which supports the existing long-term safety profile of adalimumab from clinical studies.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Strober B, Crowley J, Langley RG, et al. Systematic review of the real-world evidence of adalimumab safety in psoriasis registries. J Eur Acad Dermatol Venereol. 2018. PMID: 30067882. doi:10.1111/jdv.15203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。